ORIC PHARMACEUTICALS, INC. Operating Lease, Expense
ORIC PHARMACEUTICALS, INC. (ORIC) reported Operating Lease, Expense of $1.40 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-21.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2022-03-21
- ORIC PHARMACEUTICALS, INC. operating lease, expense for fiscal 2020 was $1.40M, a 7.69% increase from fiscal 2019.
- ORIC PHARMACEUTICALS, INC. operating lease, expense for fiscal 2019 was $1.30M.
| Period end | Operating Lease, Expense 12 month |
|---|---|
| 2020-12-31 | $1.40M 10-K · filed 2022-03-21 |
| 2019-12-31 | $1.30M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |